Traditional Chinese medicine composition for treating hyperuricemia nephropathy

Abstract

The present invention discloses a Chinese medicine composition for treating hyperuricemia nephropathy, relating to the technical field of traditional Chinese medicine. The main points of the technical solution are: prepared from the following raw materials in parts by weight: 15-45g of Rhizoma Smilacis Glabrae, 10-20g of Poria, 10-20g of Coix Seed, 5-15g of Atractylodes, and 3-9g of Licorice. The Chinese medicine composition of the present invention has the effects of clearing away heat and dampness, promoting uric acid excretion, helping to lower serum uric acid levels, thereby alleviating hyperuricemia, and can help improve kidney function and reduce the damage caused to the kidneys by excessive uric acid.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and more particularly to a traditional Chinese medicine composition for treating hyperuricemia nephropathy. Background Art

[0002] Hyperuricemia-associated nephropathy (HUA-CKD) is a chronic kidney disease caused by impaired uric acid metabolism. Elevated uric acid levels not only lead to gout but also damage kidney function, potentially leading to chronic renal failure. Clinically, treatments for HUA-CKD typically include medication, dietary changes, and lifestyle adjustments. However, due to the side effects and drug resistance associated with Western medications, a growing number of researchers and clinicians are interested in the use of Traditional Chinese Medicine (TCM) in the treatment of HUA-CKD.

[0003] Modern pharmacological studies have shown that various ingredients in traditional Chinese medicine have unique mechanisms of action in the treatment of hyperuricemia and related kidney diseases. Some ingredients in traditional Chinese medicine can reduce the production of uric acid by inhibiting the activity of xanthine oxidase. Some traditional Chinese medicines accelerate the excretion of uric acid and lower blood uric acid levels by increasing the excretion function of the renal tubules. Certain ingredients in traditional Chinese medicine have strong antioxidant and anti-inflammatory effects, which can reduce the inflammatory response of the kidneys and protect kidney tissue. Some traditional Chinese medicines can improve renal microcirculation and prevent further deterioration of renal function by dilating blood vessels and improving blood rheological properties.

[0004] According to Traditional Chinese Medicine (TCM), the pathogenesis of hyperuricemia-associated nephropathy is related to spleen deficiency, kidney deficiency, and internal accumulation of dampness and heat. When the spleen fails to function properly, dampness and turbidity cannot be transformed, leading to accumulation of dampness and heat. Over time, this accumulation of heat transforms into fire, ultimately leading to the accumulation of dampness and heat, and the upward movement of turbid pathogens, which in turn affects kidney function. The kidneys are the foundation of our constitution and govern fluid metabolism. Kidney deficiency impairs qi transformation, leading to internal accumulation of dampness and heat, and thus impaired uric acid metabolism. Based on both traditional and modern research findings and TCM theory, numerous traditional Chinese medicine combinations have been developed in recent years. These combinations, targeting different pathological mechanisms, employ multi-target, multi-pathway treatment strategies. These combinations often contain multiple synergistic Chinese medicinal ingredients, minimizing side effects while enhancing therapeutic efficacy.

[0005] The present invention finds that a traditional Chinese medicine composition consisting of Smilax glabra, Poria cocos, Coix seed, Atractylodes macrocephala, and Licorice and a traditional Chinese medicine composition prepared using the formula of the traditional Chinese medicine composition can help lower serum uric acid levels, thereby alleviating hyperuricemia, and can help improve kidney function and reduce damage to the kidneys caused by excessive uric acid. Summary of the Invention

[0006] The present invention aims to provide a traditional Chinese medicine composition for treating hyperuricemia-induced nephropathy. Another aim of the present invention is to provide a method for preparing the traditional Chinese medicine composition. A third aim of the present invention is to provide the use of the traditional Chinese medicine composition in the preparation of a medicament for lowering uric acid and improving kidney disease. The traditional Chinese medicine composition of the present invention has a certain therapeutic effect on hyperuricemia and can significantly reduce uric acid levels.

[0007] The above technical purpose of the present invention is achieved through the following technical scheme: a traditional Chinese medicine composition for treating hyperuricemia nephropathy, which is prepared from the following raw materials in parts by weight: 15-45g of Smilax glabra, 10-20g of Poria cocos, 10-20g of Coix seed, 5-15g of Atractylodes lancea, and 3-9g of Licorice.

[0008] The present invention is further configured as follows: the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30g of Smilax glabra, 15g of Poria cocos, 15g of Coix seed, 10g of Atractylodes lancea, and 6g of Licorice.

[0009] The present invention is further configured as follows: the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15g of Smilax glabra, 10g of Poria cocos, 10g of Coix seed, 5g of Atractylodes lancea, and 3g of Licorice.

[0010] Another object of the present invention is to provide a method for preparing a Chinese medicine composition for treating hyperuricemia nephropathy, comprising the following steps:

[0011] S1: Weigh each component and pharmaceutical excipient according to the above formula, crush the pharmaceutical excipient, and then sieve to obtain a uniform powder;

[0012] S2: uniformly mix all the medicinal materials and pharmaceutical excipients processed in step S1, stir thoroughly during mixing, and perform decoction multiple times;

[0013] S3: combining the decoctions obtained from each decoction in step S2 and stirring them evenly; the combined decoction is a preliminary Chinese medicine composition for treating hyperuricemia nephropathy;

[0014] S4: The combined medicinal liquid in step S3 is further concentrated in the decoction pot over a low heat. The concentrated medicinal liquid should be naturally cooled to room temperature for storage.

[0015] The present invention is further configured as follows: in step S4, the medicinal liquid is concentrated until every 1 ml of the medicinal liquid contains 2 g of the crude drug, that is, the medicinal liquid is concentrated in color and has a viscous texture, and the process is stopped.

[0016] Another object of the present invention is to provide a Chinese medicine composition for treating hyperuricemia nephropathy and its use in preparing uric acid-lowering and kidney disease-improving drugs.

[0017] The pharmacological properties of the medicine of the present invention are as follows:

[0018] Smilax glabra: sweet, light, neutral, enters the liver and stomach meridians, detoxifies and removes dampness, dredges joints, removes dampness and turbidity, clears heat and reduces swelling;

[0019] Poria: sweet, light, neutral, enters the heart, lung, spleen, and kidney meridians, promotes diuresis and eliminates dampness, strengthens the spleen and calms the mind, soothes the heart and improves intelligence, resolves phlegm and relieves cough;

[0020] Coix seed: sweet, light, slightly cold, enters the spleen, stomach, and lung meridians, promotes diuresis and eliminates dampness, strengthens the spleen and stops diarrhea, clears heat and discharges pus, and relaxes muscles and activates blood circulation;

[0021] Atractylodes: bitter, pungent, warm, enters the spleen and stomach meridians, strengthens the spleen and dries dampness, dispels wind and cold, regulates qi and stabilizes pregnancy;

[0022] Licorice: sweet, neutral, enters the spleen, stomach, heart, and lung meridians, nourishes the spleen and replenishes qi, moistens the lungs and relieves cough, harmonizes the stomach and relieves urgency, detoxifies and harmonizes various medicines.

[0023] The therapeutic mechanism of the present invention is as follows: The Chinese medicine composition contains the following five medicinal materials: Smilax glabra, Poria cocos, Coix seed, Atractylodes macrocephala, and Licorice. Each medicinal material has its own characteristics, and they work together to regulate hyperuricemia nephropathy. The therapeutic mechanism of each medicinal material and their synergistic effect are as follows:

[0024] With its detoxifying and dehumidifying properties, Chinese yam can clear out damp-heat toxins from the body and reduce the accumulation of uric acid in the body. Its function of clearing joints is suitable for joint pain and swelling symptoms caused by hyperuricemia, while promoting the excretion of uric acid and protecting kidney function. In addition, Chinese yam has certain anti-inflammatory and liver-protecting effects, which help prevent the damage of high uric acid to the kidneys and other organs; the diuretic and dehumidifying effect of Poria can effectively promote the metabolism of water in the body, help clear excess uric acid, and relieve kidney pressure. The spleen-strengthening effect can strengthen the spleen's transportation and transformation function, reduce the possibility of endogenous dampness and turbidity, and further prevent the deposition of uric acid. In addition, Poria has the effect of calming the mind and can relieve the mental stress and anxiety caused by kidney disease.

[0025] Coix seed's diuretic and dampness-removing properties can help clear dampness and promote uric acid excretion, alleviating the burden on the kidneys. Its spleen-tonifying effect can also enhance spleen and stomach function, reduce internal dampness, and prevent further uric acid deposition. Coix seed also has anti-inflammatory and immunomodulatory effects, alleviating the inflammatory response of hyperuricemia to the joints and kidneys. Atractylodes lancea's spleen-tonifying and dampness-removing properties can further strengthen the spleen and stomach's transport and transformation functions, promote water metabolism, reduce dampness formation, and facilitate uric acid excretion. Atractylodes lancea's wind-dispelling and cold-dispersing properties can improve blood circulation and prevent uric acid deposition caused by stagnation of cold and dampness. Furthermore, it can enhance the absorption and effectiveness of other herbs, strengthening the overall efficacy of the formula. Licorice's role in this formula is primarily to harmonize the various herbs and enhance the overall efficacy of the formula. It can also tonify the spleen and replenish qi, help restore spleen and stomach function, and promote uric acid metabolism. Furthermore, licorice's detoxifying properties can alleviate damage to the kidneys and other internal organs caused by uric acid accumulation, further protecting renal function.

[0026] The traditional Chinese medicine composition of the present invention comprehensively regulates the spleen and stomach functions, clears dampness and turbidity in the body, and enhances the metabolism and excretion of uric acid through multiple ways such as detoxification and dehumidification, spleen strengthening and diuresis, and dispelling wind and cold. The various medicinal materials complement each other and can effectively improve the symptoms of hyperuricemia nephropathy, reduce the burden on the kidneys, protect kidney function, and prevent further deterioration of the disease.

[0027] The medicine of the present invention is mainly used to treat spleen deficiency and dampness excess; symptoms include fatigue, loss of appetite, abdominal distension and loose stools, heaviness of limbs, dizziness, joint pain, turbid urine, pale and fat tongue, white and greasy tongue coating, and slow pulse. It has the effects of strengthening the spleen and removing dampness, and promoting diuresis and eliminating dampness.

[0028] In summary, the present invention has the following beneficial effects:

[0029] 1. The Chinese medicine composition of the present invention can effectively remove dampness and turbidity from the body, promote the excretion of uric acid, reduce the burden on the kidneys, and prevent excessive accumulation of uric acid in the body through the effects of promoting diuresis and dispelling dampness, clearing away heat and detoxifying; the medicinal materials such as Atractylodes lancea, Coix seed, and Poria in the medicine have the effects of strengthening the spleen and drying dampness, which helps to improve the weak state of the spleen and stomach, enhance the digestion and absorption function, reduce the possibility of endogenous dampness and turbidity, and thus improve the physical condition of patients with hyperuricemia.

[0030] 2. The Chinese smilax glabra and coix seed in the medicine of the present invention have anti-inflammatory effects, can reduce the inflammatory response caused by hyperuricemia, relieve joint pain and swelling symptoms, and enhance the patient's quality of life; through the synergistic effect of multiple drugs, this prescription can effectively protect kidney function, prevent kidney damage caused by uric acid accumulation, and play a good therapeutic and preventive role. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 Schematic diagram of HE staining results of kidney in an embodiment of the present invention;

[0032] Among them, Figure A is a schematic diagram of the HE staining results of the kidneys in the blank group; Figure B is a schematic diagram of the HE staining results of the kidneys in the model group; Figure C is a schematic diagram of the HE staining results of the kidneys in the traditional Chinese medicine group; Figure D is a schematic diagram of the HE staining results of the kidneys in the positive drug group. DETAILED DESCRIPTION

[0033] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, all percentages, ratios, proportions, or parts are by weight.

[0034] Example 1: A traditional Chinese medicine composition for treating hyperuricemia nephropathy, the components of the medicine include medicinal materials and pharmaceutical excipients, and is made from the following raw materials in the following weight ratios: 30g of Smilax glabra, 15g of Poria cocos, 15g of Coix seed, 10g of Atractylodes lancea, and 6g of Licorice.

[0035] The preparation method of the water decoction of the above medicine is:

[0036] S1: Preparation of medicinal materials and pharmaceutical excipients

[0037] Weigh the following medicinal materials: 30g of Smilax glabra, 15g of Poria cocos, 15g of Coix seed, 10g of Atractylodes lancea, and 6g of Licorice root;

[0038] Medicinal material processing: The medicinal excipients are crushed and then sieved to obtain a uniform powder; Poria cocos, licorice, coix seed, and Atractylodes lancea are crushed into coarse powder respectively. The mesh size of the coarse powder is generally not less than 60 mesh to ensure that the medicinal materials can fully release their active ingredients during the decoction process.

[0039] S2: Mixing and multiple decoctions of medicinal materials

[0040] Mixing medicinal materials: uniformly mix all the medicinal materials and pharmaceutical excipients processed in step S1; fully stir during mixing to ensure uniform distribution and effect of each medicinal material during the decoction process;

[0041] First decoction: Place the mixed herbs in a decoction pot and add enough water, usually 6-8 times the total amount of herbs. After soaking the herbs for about 30 minutes, start decocting. Boil over high heat first, then reduce to low heat and keep it simmering for 30-45 minutes. After the decoction is completed, filter the liquid while it is hot and leave the residue in the pot.

[0042] Second decoction: Add an appropriate amount of water to the medicinal residue, which is also 6-8 times the total amount of the medicinal materials, and repeat the above decoction process for 20-30 minutes. After the decoction is completed, filter the medicinal liquid again while it is hot;

[0043] Third decoction: According to the properties of the medicinal materials and experience, if you need to extract the medicinal effects more fully, you can perform a third decoction. The method is the same as the second time. The decoction time is 20-30 minutes. After the decoction is completed, filter the medicinal liquid again while it is hot.

[0044] S3: Decoction filtration and merging

[0045] Combine the medicinal liquid: Combine the decoctions obtained from each decoction in step S2 and stir them evenly. The combined medicinal liquid is a preliminary Chinese medicine composition for treating hyperuricemia nephropathy.

[0046] S4: Concentration and preservation

[0047] Concentrate the medicinal solution: Transfer the combined medicinal solution to a concentration device, or continue concentrating it in the decoction pot over low heat. Maintain a low temperature during the concentration process to avoid boiling the medicinal solution or destroying the medicinal ingredients. Concentrate until 2g of crude drug is contained per 1ml of the medicinal solution. At this point, the medicinal solution should have a rich color and a thick texture.

[0048] Cooling and storage: The concentrated liquid medicine should be cooled naturally to room temperature to prevent the active ingredients from being destroyed by heat. The cooled liquid medicine should be divided into sterilized glass bottles or other sealed containers, sealed and stored in a cool and dry place or refrigerated.

[0049] Example 2: A Chinese medicine composition for treating hyperuricemia nephropathy, comprising medicinal materials and pharmaceutical excipients, is prepared from the following raw materials in the following proportions by weight: 15g of Smilax glabra, 10g of Poria cocos, 10g of Coix lachryma-jobi, 5g of Atractylodes lancea, and 3g of Licorice. The water decoction of the above-mentioned medicinal materials is prepared as described in Example 1.

[0050] Experimental verification example:

[0051] 1. Test Materials

[0052] Twenty-eight SPF-grade SD rats, 6-8 weeks old, male, weighing 250-280 g, were provided by Hunan Slake Jingda Experimental Animal Co., Ltd. They were housed in separate cages at the Animal Experimentation Center of Hunan University of Chinese Medicine under the following conditions: a temperature of 22-26°C, a diurnal temperature difference of ≤3°C, a relative humidity of 40%-70%, and a 12 / 12 hour light-dark cycle. The rats had free access to food and water. This experiment was approved by the Animal Experimentation Ethics Committee of Hunan University of Chinese Medicine.

[0053] 2. Main drugs and reagents

[0054] Chinese medicine formula: 30g of wild yam, 15g of poria, 15g of coix seed, 10g of atractylodes, and 6g of licorice.

[0055] Drugs and reagents: potassium oxonate (Aladdin, catalog number: P137112), hypoxanthine (Sigma, catalog number: V900452), sodium carboxymethyl cellulose (Aladdin, catalog number: C104984), allopurinol (Aladdin, catalog number: A105386); 0.9% sodium chloride injection; uric acid test kit was purchased from Nanjing Jiancheng Bioengineering Institute.

[0056] Preparation of the above solution: Preparation of sodium carboxymethylcellulose solution: Accurately weigh 5.000g of sodium carboxymethylcellulose (CMC-Na) powder, slowly add the weighed CMC-Na into a clean 1000mL beaker, then gradually add an appropriate amount of distilled water or normal saline, and continuously stir the solution using a magnetic stirrer or a manual stirrer until the CMC-Na is completely dissolved to form a uniform colorless, transparent liquid. The concentration of the solution should be 0.5% (w / v), that is, 0.5g of CMC-Na is contained in every 100mL of solution.

[0057] Preparation of potassium oxonate solution: Using the above-prepared 0.5% CMC-Na solution as a solvent, weigh 3 g of potassium oxonate crystals, gradually add the weighed potassium oxonate crystals to 97 mL of 0.5% CMC-Na solution, and slowly stir until the potassium oxonate is completely dissolved to form a uniform solution. The resulting solution is a 3% potassium oxonate solution.

[0058] Preparation of hypoxanthine suspension: Take 10 mg of hypoxanthine crystals and suspend them in 1 mL of 0.5% CMC-Na solution to form a 10 mg / mL hypoxanthine suspension. Hypoxanthine does not dissolve completely, so it exists in a suspended form. Continuous stirring or ultrasonic vibration should be used to ensure uniform distribution of the suspension and prevent crystal precipitation.

[0059] All the prepared solutions mentioned above should be immediately placed into clean glass bottles or plastic bottles and sealed to prevent contamination; and the prepared solutions should be refrigerated and stored in a refrigerator at 4°C. Low-temperature storage can reduce the degradation of solution components, maintain the activity and stability of the solution, and prevent changes in the viscosity and uniformity of the solution.

[0060] 3. Animal Grouping, Modeling, and Drug Administration

[0061] ① Animal grouping: 28 SD rats were randomly divided into a normal group, a model group, and a Chinese medicine group, with 7 rats in each group.

[0062] ② Modeling: Except for the normal control group, rats in all groups were intraperitoneally injected with 300 mg / kg of 3% potassium oxonate suspension and gavage-administered with 100 mg / kg of hypoxanthine once daily for 7 consecutive days to establish HUA models. The drugs were continuously administered during the modeling period.

[0063] ③Administration: Chinese medicine group: 30g of Smilax glabra, 15g of Poria cocos, 15g of Coix seed, 10g of Atractylodes macrocephala, and 6g of Licorice root.

[0064] The above Chinese medicinal materials were mixed in proportion, decocted in water, filtered and concentrated to 2g of crude drug per ml.

[0065] The drug dosage was calculated according to the animal surface area-dose conversion method, based on the daily dose of crude drugs for a 70 kg adult. The uric acid-lowering formula was administered orally at 6.84 g / (kg·d).

[0066] IV. Sampling and Index Testing

[0067] 1. Modeling and sampling: After the last administration of the drug to the experimental rats, wait for 1 hour to ensure that the drug has fully taken effect in the body. Modeling should be started 1 hour after the last administration. 2 hours after modeling, the experimental animals should be anesthetized to ensure that the animals do not feel pain during the sampling process. Conventional sodium pentobarbital small animal anesthetic can be used as anesthesia. Under anesthesia, use a sterile syringe to collect blood samples from the heart or tail vein of the animal. The collected blood should be immediately placed in an anticoagulant tube to avoid blood coagulation. The collected blood sample should be centrifuged at 3000 rpm for 10 minutes at 4°C to separate the supernatant. The separated serum should be quickly transferred to a clean EP tube and stored in a -80°C refrigerator for uric acid determination.

[0068] 2. Kidney Sampling and Processing: After blood collection, the abdominal cavity was quickly opened to expose the kidneys. The kidneys were carefully removed from the abdominal cavity and the left and right kidneys were weighed using a precision balance, and their weights were recorded. The weighed left kidney was immediately placed in a pre-prepared 4% paraformaldehyde solution and fixed for 24 hours to prevent degradation of cellular structure and components. After weighing the right kidney, the kidney tissue was rapidly frozen using liquid nitrogen and immediately stored in an ultra-low temperature freezer at -80°C for subsequent molecular biology testing.

[0069] 3. Determination of uric acid, creatinine, and urea nitrogen content: According to the uric acid, creatinine, and urea nitrogen determination kit used in the experiment, take an appropriate amount of separated serum sample, perform sample pretreatment according to the requirements of the kit instructions, add the treated serum sample to the enzyme-linked immunosorbent assay plate, add various reagents according to the instructions of the kit instructions, mix well, incubate at the specified temperature of 37°C for 10 minutes, use a microplate reader to read the OD value, and measure at wavelengths of 510nm (uric acid), 546nm (creatinine), and 520nm (urea nitrogen), respectively. Calculate the specific contents of uric acid, creatinine, and urea nitrogen in the serum according to the standard curve.

[0070] 4. Hematoxylin-eosin (HE) staining to observe pathological changes in renal tissue: After fixation, the renal tissue needs to be dehydrated in a gradient ethanol solution, with each level of ethanol soaking time being 1 hour. The dehydrated tissue needs to be soaked in xylene, usually in two steps, with each soaking time being 15-30 minutes, so that the renal tissue can be completely transparent. The transparent renal tissue is placed in melted paraffin, usually embedded at 60°C. After the paraffin is completely embedded in the tissue, it is cooled and solidified, and then cut into thin slices 4-6 microns thick.

[0071] Paraffin-embedded tissue sections are placed on glass slides, dewaxed, rehydrated, and then stained with hematoxylin and eosin. Nuclei are stained with hematoxylin, and cytoplasm is stained with eosin. After staining, the slides are mounted with neutral gum, ensuring they are flat and free of bubbles. After mounting, the slides are observed using an inverted microscope, focusing on pathological changes in the renal tissue, such as tubular damage and glomerular lesions. Finally, microscopic photographs are taken to document the observed pathological changes.

[0072] 5. Statistical Processing

[0073] Statistical analysis was performed using SPSS 25.0 software. If the data conformed to a normal distribution and the variances between groups were homogeneous, the LSD method was used; if the variances were not homogeneous, the Dunnett's T3 method was used. If the data did not conform to a normal distribution, a nonparametric test was used. A P value of less than 0.05 was considered statistically significant.

[0074] 6. Test Results

[0075] The test results of the above uric acid, creatinine and urea nitrogen content determination are shown in Table 1 below:

[0076] Table 1 Uric acid, creatinine and urea nitrogen determination results

[0077]

[0078] The above-mentioned experimental results of uric acid, creatinine and urea nitrogen content determination showed that the normal group rats did not undergo any modeling operation and drug intervention, and the serum uric acid, creatinine and urea nitrogen levels remained at the basal level without obvious fluctuations. This result shows that under normal physiological conditions, the uric acid, creatinine and urea nitrogen metabolism functions of SD rats are normal; during the modeling process, the model group rats were intraperitoneally injected with 3% potassium oxonate suspension (300 mg / kg) and gavage with hypoxanthine (100 mg / kg). After 7 consecutive days, the serum uric acid, creatinine and urea nitrogen levels increased significantly, indicating that the modeling method successfully induced a hyperuricemia (HUA) model and renal function damage, verifying the effectiveness of the modeling.

[0079] The results showed that rats that received the uric acid-lowering Chinese herbal formula simultaneously with modeling had significantly lower serum uric acid, creatinine, and urea nitrogen levels than those in the model group, indicating that the Chinese herbal formula has a therapeutic effect on hyperuricemia and can effectively reduce uric acid, creatinine, and urea nitrogen levels. Statistical analysis showed that the difference in uric acid levels between the model group and the normal group was significant (P < 0.05), indicating that the model was successfully established. At the same time, the difference in uric acid levels between the Chinese herbal formula group and the model group was also significant (P < 0.05), further confirming the therapeutic efficacy of the Chinese herbal formula and its significant uric acid-lowering effect.

[0080] The above kidney HE staining results are shown in the attached Figure 1 As shown in the figure, the results of kidney HE staining showed that the renal tissue structure of the rats in the normal group was clear, the renal tubules and glomeruli were normal in morphology, and there were no obvious pathological changes. The epithelial cells of the renal tubules were arranged neatly, the cell nuclei were round and located in the center, and there was no inflammatory cell infiltration in the matrix, indicating that the renal tissue was in a healthy state. Obvious pathological changes were observed in the renal tissue of the rats in the model group. The renal tubules showed varying degrees of expansion and deformation, some renal tubular epithelial cells were necrotic and detached, and the glomerular structure was blurred. Obvious inflammatory cell infiltration was seen in the renal interstitium, indicating that the renal damage was more serious. This result is consistent with the renal damage caused by hyperuricemia, indicating that the hyperuricemia model successfully induced renal lesions.

[0081] The renal tissue structure of rats in the TCM group was significantly improved compared to the model group. The renal tubular epithelial cells were more neatly arranged, the number of necrotic and detached cells was significantly reduced, and the glomerular structure was clearer. Although mild inflammatory cell infiltration was still visible, the overall severity of the disease was significantly reduced. This suggests that the TCM formula has a protective effect against hyperuricemia-induced renal damage and can reduce the severity of the disease.

[0082] This specific embodiment is merely an explanation of the present invention and is not intended to limit the present invention. After reading this specification, those skilled in the art may make non-creative modifications to this embodiment as needed. However, as long as such modifications are within the scope of the claims of the present invention, they are protected by patent law.

Claims

1. A Chinese medicine composition for treating hyperuricemia nephropathy, characterized in that: The medicine is prepared from the following raw materials in parts by weight: 30g of Smilax glabra, 15g of Poria cocos, 15g of Coix seed, 10g of Atractylodes lancea, and 6g of Licorice root.

2. A method for preparing a Chinese medicine composition for treating hyperuricemia nephropathy, characterized by: The following steps are involved: S1: Weighing the components and pharmaceutical excipients according to the formula of claim 1, crushing the pharmaceutical excipients, and then sieving to obtain a uniform powder; S2: uniformly mix all the medicinal materials and medicinal excipients processed in step S1, stir them thoroughly, and perform decoction multiple times; S3: combining the decoctions obtained from each decoction in step S2 and stirring them evenly; the combined decoction is a preliminary Chinese medicine composition for treating hyperuricemia nephropathy; S4: The combined medicinal liquid in step S3 is further concentrated in the decoction pot over a low heat. The concentrated medicinal liquid should be naturally cooled to room temperature for storage.

3. The preparation method according to claim 2, wherein: The decoction is performed three times, with each decoction time being 30-45 minutes, 20-30 minutes, and 20-30 minutes respectively; and the decoction is concentrated until each 1 ml of the medicinal liquid contains 2 g of the crude drug.

4. Use of the traditional Chinese medicine composition for treating hyperuricemia nephropathy as claimed in claim 1 in the preparation of a medicament for treating renal tubular damage and glomerular lesions caused by hyperuricemia nephropathy.

Images